ArticleBreast cancer research : BCR2020

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.

Jason J Zoeller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.